GSK presents positive data for AREXVY, its respiratory syncytial …
WEB2 days ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …
GSK says RSV vaccine protects against disease over three seasons
WEB2 days ago · Dive Brief: Vaccine maker GSK unveiled new data Tuesday showing its respiratory syncytial virus vaccine Arexvy protected older adults over three seasons against disease caused by infection. Across the entire time period, one dose of Arexvy was 63% effective against RSV broadly, and 67% effective against severe disease, GSK said.
GSK hopes for Arexvy boost after positive Phase III data
WEB16 hours ago · GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of Arexvy maintains 62.9% efficacy in preventing RSV-related lower respiratory tract disease (LRTD) and 67.4% efficacy against severe disease over three seasons. Initially approved for adults 60+, GSK expanded use to high-risk adults aged 50-59.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
WEB1 day ago · PHILADELPHIA, October 08, 2024--GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK Presents Positive Data for AREXVY, Its Respiratory
WEB2 days ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY(Respiratory ...
GSK announces positive topline data on co-administration of AREXVY …
WEBSep 18, 2024 · AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK RSV shot 43% effective against severe disease in third year
WEB1 day ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, …
WEB13 hours ago · GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot. That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial.
- Some results have been removed